1
|
Marcu (Selaru) CA, Parlatescu I, Tovaru S, Nicolae CL, Costache M, Tovaru M. Lichen Planus of the Lip-Case Series and Review of the Literature. MEDICINA (KAUNAS, LITHUANIA) 2024; 60:987. [PMID: 38929604 PMCID: PMC11205475 DOI: 10.3390/medicina60060987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2024] [Revised: 06/08/2024] [Accepted: 06/14/2024] [Indexed: 06/28/2024]
Abstract
Background and Objectives: Lichen planus of the lip (LPL) is a chronic inflammatory condition that resembles actinic cheilitis, discoid lupus erythematosus, graft-versus-host disease, and lichenoid reaction to dental materials or drugs. The purpose of this study was to conduct a literature review on lichen planus lip involvement and to report a retrospective observational study that characterises and explores the clinical, histopathological, and evolution of the lesions in a group of patients with unique involvement of LPL. Materials and Methods: Clinical data of patients diagnosed with LPL was retrieved from the medical charts of the patients referred to the Oral Pathology Department of the "Carol Davila" University of Medicine and Pharmacy. A concurrent electronic literature research was carried out using PubMed and Web of Science from 2003 to 2023. Results: Eleven patients diagnosed with unique LPL were analysed (male/female ratio was 1.75, mean age 63.64 years ± 12.52). All patients presented lesions of the lower lip; the clinical forms were atrophic (six cases) and erosive (five cases), and the histopathological exam confirmed the diagnosis. After topical treatment with corticosteroids, most of the patients had complete remission. The literature review revealed 24 studies (sixteen case reports and eight case series) which comprised 84 patients. Isolated lip involvement was reported in 17 studies, and five articles with concomitant oral lichen planus, while two articles did not mention this criterion. Conclusions: Our study brings new data on isolated lichen planus of the lip that primarily affects the lower lip with predominance in male patients. It was reported worldwide in patients between 22 and 75 years old. Topical corticosteroids were the main treatment prescribed and they usually brought remission of the lesions. Lichen planus of the lip is a challenging diagnosis for oral health practitioner providers as well as for dermatologists.
Collapse
Affiliation(s)
| | - Ioanina Parlatescu
- Faculty of Dentistry, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania; (S.T.); (C.L.N.); (M.T.)
| | - Serban Tovaru
- Faculty of Dentistry, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania; (S.T.); (C.L.N.); (M.T.)
| | - Carmen Larisa Nicolae
- Faculty of Dentistry, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania; (S.T.); (C.L.N.); (M.T.)
| | - Mariana Costache
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania;
| | - Mihaela Tovaru
- Faculty of Dentistry, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania; (S.T.); (C.L.N.); (M.T.)
| |
Collapse
|
2
|
Umar BU, Rahman S, Dutta S, Islam T, Nusrat N, Chowdhury K, Binti Wan Ahmad Fakuradzi WFS, Haque M. Management of Atopic Dermatitis: The Role of Tacrolimus. Cureus 2022; 14:e28130. [PMID: 35990561 PMCID: PMC9387362 DOI: 10.7759/cureus.28130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/18/2022] [Indexed: 11/13/2022] Open
Abstract
Atopic dermatitis (AD) is a long-lasting inflammatory dermatological condition characterized by itchy, eczematous, sparsely tiny blisters that hold a clear watery substance. Additionally, the diseased skin can suppurate, occasionally with weeping with thickening of the affected skin. This is considered one of the top skin disorders involving both children and adult populations globally. The principal therapeutic intervention for AD is long-standing topical glucocorticoids, which have been used for several decades. Corticosteroid therapy brings several adverse drug effects (ADRs), including irreversible skin atrophy. Tacrolimus belongs to the class of calcineurin inhibitors, which is a type of immunomodulator possessing promising efficacy in treating AD. Topical tacrolimus is an effective and safe non-corticosteroid substitute treatment for AD. We reviewed the available literature to compare and institute the safety, efficacy, and effectiveness of tacrolimus when equated to corticosteroid therapy in managing AD.
Collapse
|
3
|
Walia C, Rallan NS, Premkumar A, Roy S. Clinical Evaluation of Efficacy of Triamcinolone Acetonide with Tacrolimus in the Management of Oral Lichen Planus: A Pilot Prospective Observational Study. Contemp Clin Dent 2022; 13:236-241. [PMID: 36213860 PMCID: PMC9533377 DOI: 10.4103/ccd.ccd_899_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Revised: 02/06/2021] [Accepted: 02/10/2021] [Indexed: 11/23/2022] Open
Abstract
INTRODUCTION Lichen planus (LP) is a relatively common chronic, mucocutaneous disease of autoimmune origin, involves oral mucosa, skin, scalp, nails, and genital mucosa. The prevalence of oral LP (OLP) varies worldwide, commonly seen in middle-aged and elderly people. It usually presents as symmetrical and bilateral or multiple lesions with burning sensation (BS) sometimes accompanied by pain. Corticosteroids and calcineurin inhibitors have shown promising results in the treatment of OLP, but its chronic course and unpredictable exacerbations/remission continues to result in a high degree of morbidity. The study aimed to evaluate the efficacy of intralesional triamcinolone acetonide (injection TA) combined with topical application of TA orabase and Tacrolimus (TAC) ointment for symptomatic cases of OLP. MATERIALS AND METHODS The prospective study included 52 symptomatic OLP patients to receive (0.5 ml) intralesional injection of TA once a week for the first 4 weeks followed by one injection in the 6th week along with TA mucosal paste (0.1%.) and TAC ointment (0.03%) in tapering dose till 8th week. The subjective symptoms including BS and pain were assessed on a 10 cm visual analog scale (VAS) and objective signs like size and site of the lesion were scored according to criterion scale modified by Thongprasom et al. Differences were compared after 8 weeks treatment course and follow-up observations were performed at 20th week to record any recurrent lesion. RESULTS 41 patients (78.8%) had complete remission of disease and 11 (21%) had shown partial improvement. The VAS scores for BS and pain improved significantly. Improvement was also noted with decrease in the average size of active lesions and the number of sites with treatment. The relapse was seen in 17 patients (41%) in the 20th week. CONCLUSION TA combined with TAC is a valuable therapeutic option for the treatment of symptomatic OLP. Our findings suggest that patients have shown statistically significant improvement.
Collapse
Affiliation(s)
- Cheshta Walia
- Department of Oral and Maxillofacial Pathology, Buraydah Private College, College of Dentistry and Pharmacy, Buraydah, Saudi Arabia,Address for correspondence:Dr. Cheshta Walia, Department of Oral and Maxillofacial Pathology, Buraydah Private College, College of Dentistry and Pharmacy, Buraydah 31717, Saudi Arabia. E-mail:
| | - Neelakshi Singh Rallan
- Department of Oral Pathology and Microbiology, Teerthanker Mahaveer Dental College and Research Centre, Moradabad, Uttar Pradesh, India
| | - Anu Premkumar
- Department of Oral Medicine and Radiology, Dr. Syamala Reddy Dental College, Hospital and Research Centre, Bengaluru, Karnataka, India
| | - Sudip Roy
- Department of Orthodontics and Dentofacial Orthopedics, Buraydah Private College, College of Dentistry and Pharmacy, Buraydah, Saudi Arabia
| |
Collapse
|
4
|
Kierce J, Shi Y, Klieb H, Blanas N, Xu W, Magalhaes M. Identification of specific clinical risk factors associated with the malignant transformation of oral epithelial dysplasia. Head Neck 2021; 43:3552-3561. [PMID: 34472151 DOI: 10.1002/hed.26851] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Revised: 07/19/2021] [Accepted: 08/18/2021] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Factors that increase the risk of malignant transformation of oral epithelial dysplasia (OED) are not completely elucidated. METHODS A retrospective chart review was performed assessing risk factors for transformation of OED, and cancer staging for transformed cases at Sunnybrook Health Sciences Centre. RESULTS Two-hundred four patients were diagnosed with OED, and 16.7% (34) underwent malignant transformation. Risk factors associated with transformation included: heavy tobacco smoking, excessive EtOH consumption, non-homogenous leukoplakia, size >200 mm2 , moderate dysplasia or greater than moderate, progression of dysplasia grades, and immunosuppression. Transformed cases followed for a dysplastic lesion were associated with a stage-I cancer diagnosis, and cancer cases with no prior biopsy were associated with a stage-IV diagnosis. CONCLUSIONS In addition to commonly cited risk factors, immunosuppression was associated with malignant transformation, including the use of topical steroids. Analyzing risk factors can help clinicians define risk of progression in patients with OED.
Collapse
Affiliation(s)
- Justin Kierce
- Oral & Maxillofacial Surgery, University of Toronto, Toronto, Ontario, Canada
| | - Yuliang Shi
- Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.,Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada
| | - Hagen Klieb
- Sunnybrook Health Sciences Centre, Department of Dental and Maxillofacial Sciences, Toronto, Ontario, Canada
| | - Nick Blanas
- Sunnybrook Health Sciences Centre, Department of Dental and Maxillofacial Sciences, Toronto, Ontario, Canada.,Oral & Maxillofacial Surgery, Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada
| | - Wei Xu
- Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.,Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - Marco Magalhaes
- Sunnybrook Health Sciences Centre, Department of Dental and Maxillofacial Sciences, Toronto, Ontario, Canada.,Oral Pathology and Oral Medicine, Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
5
|
Li Y, Wang Y, Li J, Ling Z, Chen W, Zhang L, Hu Q, Wu T, Cheng B, Wang Y, Xia J. Tacrolimus inhibits oral carcinogenesis through cell cycle control. Biomed Pharmacother 2021; 139:111545. [PMID: 33873145 DOI: 10.1016/j.biopha.2021.111545] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 03/21/2021] [Accepted: 03/23/2021] [Indexed: 12/29/2022] Open
Abstract
Tacrolimus (TAC, FK506) is a major calcineurin inhibitor and has been commonly used in treatments of patients with organ transplants and immune diseases. Moreover, tacrolimus is recommended by the treatment guidelines for oral potentially malignant disorders (OPMDs) such as oral lichen planus (OLP). However, whether tacrolimus increases the risk of cancer remains controversial. We observed that in a 4-Nitroquinoline N-oxide (4NQO)-induced oral carcinogenesis model, tacrolimus treatment was associated with a significantly lower ratio of cancer formation (52.94% vs. 90%) and a lower proportion of Ki67 and proliferation cell nuclear antigen (PCNA) -positive cells in lesion areas (P < 0.001). Liver, kidney, and lung functions of rats and the tumor immune microenvironment of the tongue were not affected. These observations suggest that tacrolimus blocked oral carcinogenesis through epithelial cell proliferation inhibition, independent of its immunosuppressive effects. As a processing factor, tacrolimus decreased tumor formation and cell proliferation in different stages of oral squamous cell carcinoma (OSCC) progression in vivo and in vitro. Furthermore, we investigated effects on the cell cycle and expression of related proteins. Tacrolimus induced G1/S phase arrest and significantly downregulated the expression of cyclinD1, cyclinE1, and c-Myc. These results suggest that tacrolimus induces G1/S phase arrest via inhibition of cyclinD1, cyclinE1, and c-Myc expression and retards oral cell carcinogenesis in vitro and in vivo. Thus, application of tacrolimus is a safe therapeutic strategy for treating OPMDs.
Collapse
Affiliation(s)
- Yuanyuan Li
- Hospital of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR, China
| | - Yanting Wang
- Hospital of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR, China
| | - Jie Li
- Hospital of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR, China
| | - Zihang Ling
- Hospital of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR, China
| | - Wei Chen
- Hospital of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR, China
| | - Liping Zhang
- Hospital of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR, China
| | - Qinchao Hu
- Hospital of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR, China
| | - Tong Wu
- Hospital of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR, China
| | - Bin Cheng
- Hospital of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR, China.
| | - Yun Wang
- Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR, China.
| | - Juan Xia
- Hospital of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, PR, China; Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR, China.
| |
Collapse
|
6
|
Gonzaga AKG, Lopes MLDDS, Squarize CH, Castilho RM, de Medeiros AMC, Rocha KBF, da Silveira ÉJD. Expression profile of DNA repair proteins and histone H3 lys-9 acetylation in cutaneous and oral lichen planus. Arch Oral Biol 2020; 119:104880. [PMID: 32892067 DOI: 10.1016/j.archoralbio.2020.104880] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 08/04/2020] [Accepted: 08/09/2020] [Indexed: 10/23/2022]
Abstract
OBJECTIVES To analyze the expression profile of DNA repair proteins (XRCC1 and APE1) and histone acetylation (H3K9) in oral and cutaneous lichen planus, in order to investigate potential biological markers that can clarify pathogenesis of these lesions. DESIGN AND RESULTS The total sample consisted of 89 lichen planus cases (66 oral and 23 cutaneous). Analysis of APE1 and XRCC1 expression was performed by immunohistochemistry in 44 oral and 20 cutaneous lichen planus, whereas the analysis of H3K9 acetylation was performed by immunofluorescence in 42 oral and 11 cutaneous lichen planus. RESULTS Immunoreactivity for APE1 and XRCC1 was significantly higher in cutaneous lichen planus than in oral lichen planus (P = 0.003 and P = 0.034, respectively). There was a significant and moderate positive correlation between APE1 and XRCC1 in the oral group (Rho = 0.544; P < 0.0001). In oral cases, there were no statistically significant results comparing APE1 and XRCC1 expression between reticular and erosive cases (P > 0.05). Evaluation of H9K3 histone acetylation levels did not reveal significant results comparing oral to cutaneous lichen planus, neither comparing erosive to reticular (P > 0.05). CONCLUSIONS Changes in the expression profile of the DNA repair proteins exerted greater influence in pathogenesis of cutaneous lichen planus than oral lichen planus, in addition, H3K9 histone acetylation is an epigenetic event found in both lesions.
Collapse
Affiliation(s)
| | | | - Cristiane Helena Squarize
- Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, University of Michigan, School of Dentistry, Ann Arbor, Michigan, USA
| | - Rogério Moraes Castilho
- Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, University of Michigan, School of Dentistry, Ann Arbor, Michigan, USA
| | | | | | | |
Collapse
|
7
|
Samimi M, Le Gouge A, Boralevi F, Passeron T, Pascal F, Bernard P, Agbo-Godeau S, Leducq S, Fricain JC, Vaillant L, Francès C. Topical rapamycin versus betamethasone dipropionate ointment for treating oral erosive lichen planus: a randomized, double-blind, controlled study. J Eur Acad Dermatol Venereol 2020; 34:2384-2391. [PMID: 32128907 DOI: 10.1111/jdv.16324] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2019] [Accepted: 02/18/2020] [Indexed: 01/15/2023]
Abstract
BACKGROUND Although superpotent topical corticosteroids are the first-line treatment for oral erosive lichen planus (OELP), topical rapamycin was found efficient in a previous case series. OBJECTIVES To compare the efficacy and safety of topical rapamycin and betamethasone dipropionate ointment for OELP in a randomized, double-blind trial. METHODS Patients were randomized to receive treatment with betamethasone dipropionate ointment 0.05% in Orabase® or topical rapamycin solution (1 mg/mL) on lesions twice daily for 3 months, followed by 3 months of observation. The primary outcome was clinical remission after 3 months of treatment. Secondary outcomes were clinical remission after 1 and 2 months, reduced oral pain and reduced impact on food intake after 3 months, clinical recurrence after treatment withdrawal, and adverse events. RESULTS During a 4-year period, 76 patients were randomized and 75 received treatment (rapamycin, n = 39; betamethasone, n = 36). At 3 months, 39.4% of patients with betamethasone and 27.3% with rapamycin showed clinical remission (odds ratio 0.68, 95% CI [0.24; 1.89]; P = 0.46). Rates of remission after 1 and 2 months, reduction in pain and impact on food intake after 3 months, were higher with betamethasone than rapamycin. Recurrence of oral erosions was similar between groups. Adverse events occurred in 43.6% of patients with rapamycin (mostly burning sensation, impaired taste) and 27.8% with betamethasone (mostly oral candidiasis). CONCLUSION Although the study was limited by insufficient recruitment, we did not find any superiority of topical rapamycin over betamethasone dipropionate ointment for OELP. Given the rapid remission and pain improvement in the betamethasone group, it appears that superpotent topical corticosteroids should remain the first-line treatment for OELP.
Collapse
Affiliation(s)
- M Samimi
- Department of Dermatology, University Hospital of Tours, University of Tours, Tours, France.,ISP 1282 INRA University of Tours, Tours, France
| | - A Le Gouge
- Biometrical Department, Centre d'Investigation Clinique, INSERM CIC1415, University Hospital of Tours, Tours, France
| | - F Boralevi
- Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux and INSERM U1035, Bordeaux, France
| | - T Passeron
- Department of Dermatology, CHU Nice, INSERM U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Nice, France
| | - F Pascal
- Department of Dermatology and Stomatology, Saint-Louis Hospital, AP-HP, Université Paris 7-Diderot, Paris, France
| | - P Bernard
- Department of Dermatology, Reims University Hospital, University of Reims-Champagne-Ardenne, Reims, France
| | - S Agbo-Godeau
- Department of Stomatology and Maxillo-Facial Surgery, Groupe hospitalier Pitié-Salpêtrière-Charles-Foix, AP-HP, Paris, France
| | - S Leducq
- Department of Dermatology, University Hospital of Tours, University of Tours, Tours, France.,Biometrical Department, Centre d'Investigation Clinique, INSERM CIC1415, University Hospital of Tours, Tours, France
| | - J C Fricain
- Department of Dentistry and Oral Health, Inserm U1026 Bioingénierie Tissulaire - BioTis, Bordeaux, University Hospital of Bordeaux, France
| | - L Vaillant
- Department of Dermatology, University Hospital of Tours, University of Tours, Tours, France
| | - C Francès
- Department of Dermatology and Allergology, Hospital Tenon, Université Paris VI Pierre et Marie Curie, Sorbonnes Universités, Paris, France
| |
Collapse
|
8
|
Shavit E, Hagen K, Shear N. Oral lichen planus: a novel staging and algorithmic approach and all that is essential to know. F1000Res 2020; 9. [PMID: 32226613 PMCID: PMC7096219 DOI: 10.12688/f1000research.18713.1] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/19/2020] [Indexed: 01/04/2023] Open
Abstract
Lichen planus (LP) is a chronic autoimmune disease. Oral lesions may occur in isolation or in combination with other affected muco-cutaneous sites. Oral LP (OLP) may present as one of the various manifestations of LP or may present as a disease sui generis with a broad range of severity. Despite this disease targeting the oral mucosa, its great impact on quality of life is underrated. In this article, we provide an updated review of the pathophysiology and epidemiology of OLP and offer guidance for its diagnosis and management. We also propose an algorithmic approach to the clinical forms of OLP and a novel staging system to facilitate management decisions.
Collapse
Affiliation(s)
- Eran Shavit
- Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.,Dermatology Unit, Barzilai University Medical Center, Ashkelon, Israel.,Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, Israel
| | - Klieb Hagen
- Department of Dentistry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.,Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - Neil Shear
- Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.,Department of Medicine (Dermatology, Clinical Pharmacology, and Toxicology), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.,Department of Pharmacology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
9
|
Thongprasom K. Challenges in using topical calcineurin inhibitors as a treatment for recalcitrant oral lichen planus. Br J Dermatol 2019; 181:1120. [PMID: 31361328 DOI: 10.1111/bjd.18304] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- K Thongprasom
- Oral Medicine Department, Faculty of Dentistry, Chulalongkorn University, Bangkok, 10330, Thailand
| |
Collapse
|
10
|
Husein‐ElAhmed H, Gieler U, Steinhoff M. Lichen planus: a comprehensive evidence‐based analysis of medical treatment. J Eur Acad Dermatol Venereol 2019; 33:1847-1862. [DOI: 10.1111/jdv.15771] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2018] [Accepted: 06/21/2019] [Indexed: 12/15/2022]
Affiliation(s)
- H. Husein‐ElAhmed
- Department of Dermatology and Venereology Hospital de Baza Granada Spain
- Translational Research Institute Academic Health System Medical School Hamad Medical Corporation Doha Qatar
| | - U. Gieler
- Translational Research Institute Academic Health System Medical School Hamad Medical Corporation Doha Qatar
- Department of Dermatology and Venereology Hamad Medical Corporation Doha Qatar
| | - M. Steinhoff
- Translational Research Institute Academic Health System Medical School Hamad Medical Corporation Doha Qatar
- Department of Dermatology and Venereology Hamad Medical Corporation Doha Qatar
- College of Medicine Weill Cornell Medicine‐Qatar Doha Qatar
- Medical School Qatar University Doha Qatar
- College of Medicine Weill Cornell University New York NY USA
| |
Collapse
|
11
|
Sun S, Liu J, Zhong B, Wang J, Jin X, Xu H, Yin F, Liu T, Chen Q, Zeng X. Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta‐analysis. Br J Dermatol 2019; 181:1166-1176. [PMID: 30903622 DOI: 10.1111/bjd.17898] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/18/2019] [Indexed: 02/05/2023]
Affiliation(s)
- S.‐L. Sun
- State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management West China Hospital of Stomatology Sichuan University Chengdu Sichuan 610041 China
| | - J.‐J. Liu
- State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management West China Hospital of Stomatology Sichuan University Chengdu Sichuan 610041 China
| | - B. Zhong
- Department of Otolaryngology, Head and Neck Surgery West China Hospital Sichuan University Chengdu Sichuan 610041 China
| | - J.‐K. Wang
- State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management West China Hospital of Stomatology Sichuan University Chengdu Sichuan 610041 China
| | - X. Jin
- College of Stomatology Chongqing Medical University Chongqing Key Laboratory of Oral Diseases and Biomedical Sciences Chongqing 401147 China
| | - H. Xu
- State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management West China Hospital of Stomatology Sichuan University Chengdu Sichuan 610041 China
| | - F.‐Y. Yin
- State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management West China Hospital of Stomatology Sichuan University Chengdu Sichuan 610041 China
| | - T.‐N. Liu
- State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management West China Hospital of Stomatology Sichuan University Chengdu Sichuan 610041 China
| | - Q.‐M. Chen
- State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management West China Hospital of Stomatology Sichuan University Chengdu Sichuan 610041 China
| | - X. Zeng
- State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management West China Hospital of Stomatology Sichuan University Chengdu Sichuan 610041 China
| |
Collapse
|
12
|
Thongprasom K. Oral lichen planus: Challenge and management. Oral Dis 2018; 24:172-173. [PMID: 29480607 DOI: 10.1111/odi.12712] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2017] [Accepted: 07/10/2017] [Indexed: 12/21/2022]
Affiliation(s)
- K Thongprasom
- Oral Medicine Department, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand
| |
Collapse
|
13
|
New Functions of Classical Compounds against Orofacial Inflammatory Lesions. MEDICINES 2018; 5:medicines5040118. [PMID: 30388792 PMCID: PMC6313344 DOI: 10.3390/medicines5040118] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Revised: 10/11/2018] [Accepted: 10/13/2018] [Indexed: 01/12/2023]
Abstract
Anti-inflammatory agents have been widely used to ameliorate severe inflammatory symptoms of a number of diseases, and such therapeutics are particularly useful for diseases with intolerable pain without significant mortality. A typical example of this is a disease known as stomatitis; although stomatitis itself is not a life-threatening disease, it severely impairs the individual’s quality of life, and thus a standard therapeutic strategy for it has already been established. The topical application of a bioactive agent is quite easy, and a strong anti-inflammatory agent can be used without significant adverse effects. In contrast, natural products with relatively mild bioactivity are used for systemic intervention. However, new aspects of classical drugs used in these established therapeutic methods have recently been discovered, which is expanding the utility of these compounds to other oral diseases such as osteoarthritis of temporomandibular joints (TMJ-OA). In this review article, after summarizing the general concept and pathobiology of stomatitis, its established therapeutics are explained. Thereafter, recent advances in the research into related compounds, which is uncovering new biological functions of the agents used therein, are introduced. Indeed, regenerative therapeutics for TMJ-OA may be developed with the classical compounds currently being used.
Collapse
|
14
|
Siponen M, Huuskonen L, Kallio-Pulkkinen S, Nieminen P, Salo T. Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus: a pilot randomized controlled trial. Oral Dis 2017; 23:660-668. [PMID: 28168769 DOI: 10.1111/odi.12653] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 12/26/2016] [Accepted: 01/15/2017] [Indexed: 01/06/2023]
Abstract
OBJECTIVE To carry out a double-blind randomized controlled trial (RCT) to compare the effectiveness of topical tacrolimus (TAC), triamcinolone acetonide (TRI), and placebo (PLA) in symptomatic oral lichen planus (OLP). SUBJECTS AND METHODS A clinical score (CS, range 0-130) was developed to measure the clinical signs and symptoms of OLP. Twenty-seven OLP patients with a CS of ≥20 were randomly allocated to receive 0.1% TAC ointment (n = 11), 0.1% TRI paste (n = 7), or Orabase® paste as PLA (n = 9) for 3 weeks. If the CS dropped ≥20% (interpreted as response), the patients continued the same medication for another 3 weeks. If the CS dropped <20% or increased (non-response), the patients were switched to TAC for 6 weeks. A 6-month follow-up period ensued. The primary outcome variable was the change in CS from baseline to week 3. In primary outcome analysis, CS values between the treatment arms were compared. RESULTS Tacrolimus and TRI were more effective (P = 0.012 and 0.031, respectively) than PLA in reducing the CS at week 3. No difference in the efficacy was noted between TAC and TRI (P = 0.997). CONCLUSIONS This pilot RCT provides evidence for the effectiveness of TAC and TRI over PLA in the management of OLP.
Collapse
Affiliation(s)
- M Siponen
- Institute of Dentistry, University of Oulu, Oulu, Finland.,Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.,Department of Oral and Maxillofacial Diseases, Kuopio University Hospital, Kuopio, Finland
| | - L Huuskonen
- Institute of Dentistry, University of Oulu, Oulu, Finland
| | | | - P Nieminen
- Medical Informatics and Statistics Research Group, University of Oulu, Oulu, Finland
| | - T Salo
- Institute of Dentistry, University of Oulu, Oulu, Finland.,Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.,Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.,Medical Research Center, Oulu University Hospital, Oulu, Finland
| |
Collapse
|